Bio-Rad Laboratories (NYSE:BIO) Azioni

Bio-Rad Laboratories

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. Class B Common Stock

Bioage Labs Inc

BIOASIS TECHNOLOGIES INC by Bioasis Technologies Inc.

Bioasis Technologies Inc

Biocept Inc COM PAR $0.0001 NEW 2023

Biocept Inc

Bio Essence Corp

Blue Biofuels Inc

BIOCARTIS GROUP NV by BIOCARTIS GROUP NV

BioGaia AB

Biome Grow Inc

Biolase Inc COM PAR $.001 NEW

Biolase Inc

BIONITROGEN HLDGS CORP by BioNitrogen Holdings Corp.

BioNitrogen Holdings Corp

Bioqual Inc

Biora Therapeutics Inc

BIORA THERAPEUTCS INC by Biora Therapeutics, Inc.

BioPassport Token

SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

Bioceres Crop Solutions Corp. - Ordinary Shares

Bioceres Crop Solutions Corp

Biosyent Inc

Stocks are headed for weekly gains, with the Dow Jones dipping slightly and the S&amp;P 500 and Nasdaq trading just above the flatline Friday. Traders are digesting weaker-than-expected retail sales and the potential for peace talks<a href="https://www.benzinga.com/news/global/25/02/43732115/explosion-rocks-chernobyl-nuclear-site-as-zelenskyy-signals-readiness-for-peace-talks"> between Russia and Ukraine.&nbsp;</a>
Retail sales in the U.S. fell 0.9% month-over-month in January, significantly worse than the anticipated 0.1% drop. However, markets are largely shrugging off the weaker-than-expected retail sales figures which were likely affected by January's cold weather and California wildfires, as well as the upward revision of December results.
Geopolitical tensions eased slightly after Ukrainian President Volodymyr Zelenskyy<a href="https://www.benzinga.com/news/global/25/02/43732115/explosion-rocks-chernobyl-nuclear-site-as-zelenskyy-signals-readiness-for-peace-talks"> told reporters</a> at the Munich Security Conference on Friday that he is willing to participate in Trump&#8217;s peace initiative and eventual talks with Russia.
The price of Crude Oil slid another 0.52% Friday and is down 9.9% over the past month as the market reacted to President Donald Trump&#8216;s plans to impose reciprocal tariffs on trade partners and news of potential peace talks to end the war in Ukraine.
The yield on the 10-year U.S. Treasury note fell to below the 4.5% threshold on Friday, extending its pullback after January's retail sales data may have indicated some weakness in the U.S. consumer. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rose 0.7%. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose above the $98,000 level on a midday rally Friday and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) climbed more than 7%. 
<h2 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100 </td>
<td>19,988.34</td>
<td>0.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,116.90</td>
<td>0.03%</td>
</tr>
<tr>
<td>Dow Jones </td>
<td>44,602.67</td>
<td>-0.24%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,278.93</td>
<td>-0.14%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched up 0.3% to $609.92</li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.23% at $446.24</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.27% to $537.34.&nbsp;</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.14% to $225.82.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) dipped 0.14% to $226.78</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) rose 0.72% to $90.36.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Friday's Stock Movers:&nbsp;</h2>
Shares of Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) and SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) tanked after NVIDIA Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) latest 13F filing revealed it had dissolved its stakes in both companies.&nbsp;
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>DraftKings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)&nbsp;</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>)&nbsp;</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)&nbsp;</li>
<li>JFrog, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>)&nbsp;</li>
<li>Wynn Resorts Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>)&nbsp;</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)&nbsp;</li>
<li>Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)&nbsp;</li>
<li>Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>)&nbsp;</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)&nbsp;</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>)&nbsp;</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>)&nbsp;</li>
<li>Bio-Rad Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>)&nbsp;</li>
</ul>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a></li>
</ul>
Image: Shutterstock

$BTC

$XRP

COIN

SPDR Dow Jones Industrial Average ETF Trust

DKNG

DXCM

FROG

MRNA

NVDA

PANW

PCOR

ROKU

SERV

SOUN

iShares Trust Barclays 20+ Year Treasury Bond Fund

UDMY

WYNN

Select Sector SPDR-Consumer Discretionary

Stocks Head For Weekly Gains, US Treasury Yields Fall Below 4.5%: What's Driving Markets Friday?

WIIM

Bio-Rad Laboratories shares are trading lower after the company missed Q4 revenue estimates.

News

Guidance

Bio-Rad Currently Expects FY25 Adj. Currency-Neutral Revenue Growth Of 1.5% - 3.5% And Adj Operating Margin Of 13.0% - 13.5%

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) reported quarterly earnings of $2.90 per share which beat the analyst consensus estimate of $2.86 by 1.4 percent. This is a 6.45 percent decrease over earnings of $3.10 per share from the same period last year. The company reported quarterly sales of $667.50 million which missed the analyst consensus estimate of $679.30 million by 1.74 percent. This is a 2.01 percent decrease over sales of $681.18 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Bio-Rad Laboratories Q4 2024 Adj EPS $2.90 Beats $2.86 Estimate, Sales $667.50M Miss $679.30M Estimate

The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025.

Bio-Rad Offers To Buy  All Equity Interests In Digital PCR Developer Stilla Technologies; No Terms Disclosed

ABNB

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

CROX

CYBR

DDOG

DNOW

EEFT

EGAN

ELME

ELVA

FBRT

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Equal-Weight and lowers the price target from $360 to $345.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $345

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 47.8% to $1.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares increased by 36.89% to $2.56. The market value of their outstanding shares is at $3.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares rose 19.82% to $1.39. The market value of their outstanding shares is at $3.8 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock increased by 19.75% to $6.75. The company's market cap stands at $8.6 million. </li>
<li>Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) shares rose 19.14% to $41.88. The company's market cap stands at $6.5 billion. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) stock rose 17.39% to $5.94. The company's market cap stands at $336.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares declined by 14.1% to $7.6 during Tuesday's pre-market session. The market value of their outstanding shares is at $276.3 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares fell 12.47% to $0.13. The market value of their outstanding shares is at $10.7 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock decreased by 10.94% to $0.57. The company's market cap stands at $10.4 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock fell 10.64% to $2.52. The market value of their outstanding shares is at $124.9 million. </li>
<li>Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) shares fell 9.76% to $1.11. The company's market cap stands at $47.7 million. </li>
<li>Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) stock decreased by 9.1% to $310.0. The company's market cap stands at $8.8 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEON

AKYA

BDMD

BMRA

DSGN

DWTX

HSDT

RDHL

RPID

TNFA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $470.25, along with a high estimate of $481.00 and a low estimate of $450.00. Witnessing a positive shift, the current average has risen by 10.91% from the previous average price target of $424.00.
<img src="https://www.benzinga.com/files/images/story/2025/1736892010_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bio-Rad Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$481.00</td>
<td>$481.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$481.00</td>
<td>$369.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$469.00</td>
<td>$446.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bio-Rad Laboratories. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bio-Rad Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bio-Rad Laboratories's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bio-Rad Laboratories analyst ratings.</a>
<h2>About Bio-Rad Laboratories</h2>
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
<h3>Breaking Down Bio-Rad Laboratories's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Bio-Rad Laboratories showcased positive performance, achieving a revenue growth rate of 2.79% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bio-Rad Laboratories's net margin is impressive, surpassing industry averages. With a net margin of 100.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bio-Rad Laboratories's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 9.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bio-Rad Laboratories's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Bio-Rad Laboratories's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Bio-Rad Laboratories In The Eyes Of 4 Experts

RBC Capital analyst Conor McNamara reiterates Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Outperform and maintains $481 price target.

Reiteration

RBC Capital Reiterates Outperform on Bio-Rad Laboratories, Maintains $481 Price Target

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Outperform and raises the price target from $369 to $481.

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $481

General

BIOA

CORRECTION: Bioage Labs Ticker Is "BIOA"

Bio-Rad Laboratories shares are trading higher after Citigroup maintained a Buy rating on the stock and raised its price target from $400 to $450.

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Buy and raises the price target from $400 to $450.

Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $450

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Outperform and raises the price target from $446 to $469.

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $469

Bio-Rad Laboratories shares are trading higher after the company reported better-than-expected Q3 financial results.

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) reported quarterly earnings of $2.01 per share which beat the analyst consensus estimate of $1.16 by 73.28 percent. The company reported quarterly sales of $649.729 million which beat the analyst consensus estimate of $628.174 million by 3.43 percent. This is a 2.79 percent increase over sales of $632.124 million the same period last year.

Bio-Rad Laboratories Q3 2024 Adj. EPS $2.01 Beats $1.16 Estimate, Sales $649.729M Beat $628.174M Estimate

Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $378.4, a high estimate of $401.00, and a low estimate of $340.00. This upward trend is evident, with the current average reflecting a 4.17% increase from the previous average price target of $363.25.
<img src="https://www.benzinga.com/files/images/story/2024/1727791258_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Bio-Rad Laboratories among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$340.00</td>
<td>-</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$401.00</td>
<td>$401.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$401.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bio-Rad Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Bio-Rad Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bio-Rad Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bio-Rad Laboratories's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bio-Rad Laboratories analyst ratings.</a>
<h2>Unveiling the Story Behind Bio-Rad Laboratories</h2>
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
<h3>Financial Milestones: Bio-Rad Laboratories's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Bio-Rad Laboratories's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -6.26%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Bio-Rad Laboratories's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -339.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bio-Rad Laboratories's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -27.36%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -19.42%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.21, Bio-Rad Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Bio-Rad Laboratories

Citigroup analyst Patrick Donnelly upgrades Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) from Neutral to Buy and raises the price target from $350 to $400.

Upgrades

Citigroup Upgrades Bio-Rad Laboratories to Buy, Raises Price Target to $400

The S&amp;P 500 is a widely recognized benchmark for the US stock market, and it has undergone reshuffling due to the quarterly rebalancing process. This shake-up, driven by shifts in company performance and market capitalization, provides a unique lens into the evolving dynamics of the business world. The inclusion of several companies reflects a changing market terrain. Conversely, the departure of others underscores the challenges and transitions faced within their respective industries.&nbsp;
<h2>A Glimpse Into the S&amp;P 500</h2>
The S&amp;P 500 index is a market capitalization-weighted index, meaning that companies with a larger market cap have a more significant influence on the index&#39;s performance. This index is a barometer of the US stock market, offering investors a diversified representation of the largest publicly traded companies. Each quarter, S&amp;P Dow Jones Indices carefully reviews and adjusts the S&amp;P 500 to reflect changes in company performance and market capitalization. The most recent rebalancing saw three companies join the index and three companies leave the index.&nbsp;
<h3>Palantir: Data Analytics Powerhouse Enters the Big League</h3>
Palantir Technologies (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pltr#NYSE">PLTR</a>) is a leading data analytics and software company that has joined the S&amp;P 500 index, signifying its significant growth and market influence. Palantir specializes in real-time data analysis and prediction services, leveraging advanced artificial intelligence (AI) technologies to unlock insights for diverse clients, including government agencies, financial institutions, and healthcare organizations.
Palantir&#39;s stock has experienced a remarkable 160% surge over the past 12 months and over a 100% increase year-to-date (YTD), reflecting the increasing demand for data-driven solutions. The company&#39;s expertise has attracted significant contracts, including a $480 million deal with the US Department of Defense. This commitment from the defense sector, combined with a growing commercial presence, underscores Palantir&#39;s adaptability across various industries.
Palantir&#39;s inclusion in the S&amp;P 500 is a significant milestone leading to increased investor awareness, access to a broader range of investors, and inclusion in various index funds. This inclusion solidifies Palantir&#39;s position as a significant player in the expanding data analytics sector.
<h3>Dell Technologies: A Technology Giant Reinforces Its Position</h3>
Dell Technologies (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dell#NYSE">DELL</a>) is a long-standing leader in the technology industry, and it has further cemented its standing by joining the ranks of the S&amp;P 500. The company&#39;s diverse portfolio, encompassing computer hardware, software, and comprehensive IT solutions, positions it as a major player in the ever-evolving technology sector.
Dell&#39;s enduring success stems from its ability to adapt to changing market demands and innovate across its key segments: PCs, servers, storage, and software.
The company&#39;s recent performance reflects this adaptability, with a healthy stock price increase of 67% over the past 12 months and over 50% YTD. This growth trajectory is driven by Dell&#39;s commitment to expanding its product offerings, particularly in cloud computing and cybersecurity, which are crucial for businesses navigating an increasingly complex digital environment.
Dell&#39;s inclusion in the S&amp;P 500 signifies its continued relevance in the technology industry and signals a strong potential for further growth. As the company leverages its comprehensive solutions and embraces emerging technological trends, investors will watch closely to see how Dell continues navigating the changes happening in the tech sector.&nbsp;
<h3>Erie Indemnity: A Steady Hand in a Volatile Market</h3>
While Palantir and Dell represent the cutting edge of tech innovation, Erie Indemnity (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/erie#NASDAQ">ERIE</a>) offers a different perspective on the S&amp;P 500. This property and casualty insurance company is known for its focus on specific market niches and for providing a steady hand in a volatile market.
Erie Indemnity stands out for its deep expertise in the auto insurance market, a segment where it has built a solid reputation for its customer-centric approach and competitive pricing. This strategic focus has been a key driver of its success, allowing it to navigate industry fluctuations and build a loyal customer base.
Despite the challenges faced by the insurance industry, Erie Indemnity has maintained consistent growth. Its stock has gained around 80% over the past 12 months and 55% YTD, showcasing a track record of steady growth. This performance reflects the company&#39;s ability to manage risk effectively and cater to the evolving needs of its target audience. As the auto insurance market continues to evolve, Erie Indemnity&#39;s focus on niche expertise and its commitment to financial health make it an attractive investment option for those seeking consistent, stable returns.
<h2>Departing Companies: A Look at Industry Shifts and Market Performance</h2>
The quarterly rebalancing of the S&amp;P 500 often sees companies move to smaller indices, reflecting changes in market dynamics and adjustments in their respective industries.&nbsp;
<h3>American Airlines: Navigating Turbulent Skies</h3>
American Airlines (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aal#NASDAQ">AAL</a>) has faced significant headwinds in recent months. The company&#39;s stock price has declined by 15% over the past 12 months and 20% YTD, reflecting the challenging operating environment for airlines.
Factors such as rising fuel costs, increased competition, and the ongoing uncertainties in the travel sector have contributed to these declines.
American Airlines&#39; transition to the S&amp;P MidCap 400 reflects these challenges and signals the company&#39;s current market position within the broader airline industry.
<h3>Etsy: A Handcrafted Marketplace With Growing Competition</h3>
Etsy (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etsy#NASDAQ">ETSY</a>) is an online marketplace for handmade and vintage goods that has also experienced stock price declines, falling by 16% over the past 12 months and 34% YTD.
This decline can be attributed to several factors, including growing competition from other online marketplaces, the increasing popularity of mass-produced goods, and evolving consumer preferences.
Etsy&#39;s shift to the S&amp;P SmallCap 600 index reflects its current position within the increasingly competitive e-commerce sector.
<h3>Bio-Rad Laboratories: Changing Trends in Life Sciences</h3>
Bio-Rad Laboratories (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bio#NYSE">BIO</a>) is a leader in life sciences research and diagnostics, and the company has experienced a stock price decline of nearly 15% in the past three months and 6% over the past year.
These fluctuations are linked to broader life science industry trends, including regulatory changes, R&amp;D investment levels, and the evolving terrain of scientific research.
Bio-Rad&#39;s move to the S&amp;P MidCap 400 index reflects these market dynamics and signals the company&#39;s current position within the life sciences sector.
<h2>S&amp;P 500 Rebalancing: A Glimpse Into Market Dynamics</h2>
The recent S&amp;P 500 rebalancing gives investors a snapshot of the evolving market terrain. The inclusion of data analytics leader Palantir Technologies and tech giant Dell Technologies signals the growing significance of these sectors. Meanwhile, the departure of companies like American Airlines reflects certain industries&#39; challenges. Investors can gain valuable insights into potential growth areas and industry trends by keeping an eye on the companies entering and leaving the index.
The article &quot;<a href="https://www.marketbeat.com/originals/s-and-p-500-shake-up-new-entrants-driving-market-momentum/">S&amp;P 500 Shake-Up: New Entrants Driving Market Momentum</a>&quot; first appeared on MarketBeat.

Large Cap

Mid Cap

Offerings

Contracts

Travel

Markets

Tech

Trading Ideas

Insurance

DELL

ERIE

ETSY

PLTR

S&P 500 Shake-Up: New Entrants Driving Market Momentum

Press Releases

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Bio-Rad Reports Third-Quarter 2024 Financial Results

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Bio-Rad's Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Oncocyte Prices $29.1 Million Equity Offering

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Bio-Rad Laboratories

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO